International Society for antiviral research

Opening Session and Plenary Speakers

Chaired by Kara Carter and Kathie Seley-Radtke

Ken Duncan, Bill & Melinda Gates Foundation

What role can foundations play in driving innovation globally in antiviral development

Carl W. Dieffenbach, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Drug development for viruses of pandemic potential, Where are we now and where are we going?  

Gertrude Elion Memorial Award Lecture

Chaired by Kara Carter

George Painter, Emory University School of Medicine, Emory Institute of Drug Development, and Drug Innovation Ventures at Emory

2022 Gertrude Elion Memorial Award Recipient 

Developing a drug during a pandemic: Molnupiravir as a treatment for SARS-CoV-2 infection

Antonín Holý Memorial Award Lecture

Chaired by Kathie Seley-Radtke

Mark von Itzstein, Institute for Glycomics at Griffith University 

2022 Antonín Holý Award Recipient 

Guided anti-viral drug discovery– a tale of two viruses

Non-coronavirus Respiratory Viruses

Chaired by Kathie Seley-Radtke and Mark von Itzstein

Ralf Altmeyer, Medusa Therapeutics Limited

Targeting functional condensates of negative strand RNA viruses 

George F. Gao, Institute of Microbiology, Chinese Academy of Sciences

Talk Title TBD

Anne Moscona, Columbia University Vagelos College of Physicians & Surgeons

Inhibiting entry of human paramyxoviruses

Additional short presentations

William Prusoff Memorial Award Lecture

Chaired by Kara Carter

Priscilla Yang, Stanford University School of Medicine

2022 William Prusoff Memorial Award Recipient

Targeted protein degradation as an antiviral strategy

Retroviruses and Other Viruses 

Chaired by Graciela Andrei and Chris Meier

Marina Lusic, University Hospital Heidelberg

Title TBD

Lisa Oestereich, Bernhard-Nocht-Institut for Tropical Medicine

Antiviral therapy for Lassa Fever

Shan-Lu Liu, The Ohio State University

Host factors modulating viral entry and release

Additional short presentations

Poster Session 1

Light refreshments provided

Antonín Holý Memorial Award Lecture

Chaired by Kara Carter

Kathie Seley-Radtke, University of Maryland Baltimore County (UMBC)

2020 Antonín Holý Award Recipient 

Flex-nucleosides – a strategic approach to broad-spectrum antiviral therapeutics

Broad Spectrum Antiviral Drugs and Pandemic Preparedness

Chaired by Ann Kwong and Subhash Vasudevan

Jeffrey Glenn, Stanford University School of Medicine

Host-targeting broad-spectrum antivirals for pandemic preparedness

Rolf Hilgenfeld, University of Lübeck, Institute of Molecular Medicine

The SARS-CoV-2 main protease: structures, inhibitors, and mutations

Marco Vignuzzi, Institut Pasteur, Paris

Virus evolution and antiviral research

Additional short presentations

Poster Session 2

Lunch provided

Women in Science Award Lecture

Chaired by Rhonda Cardin

Christina Spiropoulou, US Centers for Disease Control and Prevention

2022 Women in Science Speaker Award Recipient 

Fighting Viral Hemorrhagic fevers: From the benches to the trenches

Arboviruses

Chaired by Andrea Brancale and Luis Schang

Leen Delang, KU Leuven

Antiviral strategies for arboviruses: a ‘buzzing’ role for the mosquito vector?

Feng Gu, Novartis Institute for Tropical Diseases

NITD688: a pan-serotypic NS4B inhibitor against dengue virus

Amy Hartman, University of Pittsburgh Graduate School of Public Health

New insights into cellular infection by the mosquito-transmitted Rift Valley fever virus

Additional short presentations

Diversity Speaker Award Lecture

Chaired by Ann Kwong

 J. Victor Garcia-Martinez, University of North Carolina, Chapel Hill

2022 Diversity Speaker Award Recipient 

The COVID-19 pandemic: A view from the bench

Coronaviruses

Chaired by Craig Cameron and Kara Carter

Sara Cherry, University of Pennsylvania

COVID-19: Antiviral discovery pipeline

David Dulin, Vrije Universiteit Amsterdam, Faculty of Sciences/Division of Physics and Astronomy

Targeting the replication-transcription machinery of SARS-CoV-2: a single molecule perspective

Lee Arnold, Pardes Biosciences

Profile of PBI-0451 an orally administered 3CL protease inhibitor of SARS-CoV-2 for COVID-19

Additional short presentations

Hepatitis and Herpes Viruses

Chaired by Jerome Deval and Grace Zhou

William Delaney, Assembly Bio

Advances in the development of HBV core inhibitors for the treatment of Chronic Hepatitis B

Pinghui Feng, University of Southern California, Herman Ostrow School of Dentistry

Explore herpesvirus infection to probe the roles of protein deamidation   

Fabien Zoulim, Hospices Civils de Lyon, INSERM Unit 1052

Clinical update on viral RNA targeting agents for chronic hepatitis B  

Additional short presentations